Novel, Emerging Approaches Set the Stage for Advancement in cGVHD
September 8th 2021In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.
Read More
Alrizomadlin/Pembrolizumab Induces Early Efficacy in Unresectable Melanoma or Advanced Solid Tumors
June 8th 2021The addition of alrizomadlin to pembrolizumab yielded promising preliminary efficacy and was tolerable in patients with unresectable or metastatic melanoma or advanced solid tumors that have been resistant to immunotherapy agents.
Read More
Treatment with intra-tumoral SD-101 in combination with pembrolizumab and paclitaxel resulted in a non-statistically significant increase in estimated pathological complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer across 3 HER2-negative biomarker signature groups.
Read More
Parsaclisib/Ruxolitinib Improves SVR and Symptom Burden in Myelofibrosis
April 11th 2021The combination of parsaclisib and ruxolitinib has resulted in the improvement of spleen volume reduction and symptom burden in patients with myelofibrosis who have previously experienced a suboptimal response to a standard dose of single-agent ruxolitinib.
Read More
Repotrectinib Elicits Early Responses in ROS1+ Metastatic NSCLC
January 31st 2021January 31, 2021 - Repotrectinib, a next-generation ROS1 and TRK TKI, has demonstrated encouraging objective responses with acceptable tolerability in patients with ROS1 fusion–positive non–small cell lung cancer.
Read More
Anlotinib Induces PFS Benefit in RAS/BRAF Wildtype+ mCRC
January 15th 2021January 15, 2021 - Anlotinib, a multitarget kinase inhibitor, was found to significantly improve progression-free survival with a manageable safety profile when used in Chinese patients with refractory metastatic colorectal cancer.
Read More
Ki-67 Can Be Used to Select Abemaciclib for Patients With High-Risk Early Breast Cancer
December 10th 2020December 10, 2020 - Treatment with abemaciclib in combination with endocrine therapy significantly reduced the risk of invasive disease recurrence or death in patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer who had high Ki-67 tumors, suggesting that this feature can be used in conjunction with high-risk features to select patients for abemaciclib in the adjuvant setting.
Read More
Ponatinib Elicits High Responses, Robust Outcomes in CP-CML Following TKI Failure
December 8th 2020December 7, 2020 - Ponatinib resulted in high response rates and robust survival outcomes in patients with chronic-phase chronic myeloid leukemia who have progressed on previous treatment with a second-generation TKI.
Read More
CD47-Directed TTI-622 Elicits Early Efficacy Signals in Relapsed/Refractory Lymphoma
December 6th 2020December 6, 2020 — TTI-622, an investigational CD47 inhibitor, showed preliminary signs of clinical activity with a manageable safety profile among patients with relapsed/refractory lymphoma.
Read More
Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma
September 21st 2020The feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demonstrated in the phase 1b TRAMUNE trial.
Read More
QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial
September 20th 2020Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.
Read More
Study Explores Genomics of Race in Prostate Cancer
August 6th 2020Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.
Read More
ctDNA Clearance Shows Correlation With PFS Improvement in EGFR+/MET+ NSCLC
June 23rd 2020Circulating tumor DNA clearance of EGFR mutation may be predictive of prolonged progression-free survival for patients with EGFR-mutant, MET-amplified non–small cell lung cancer with detectable ctDNA at baseline.
Read More
Avelumab Controls hCG Levels Lead to Remissions in Gestational Trophoblastic Tumors
May 29th 2020Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.
Read More
Scoring System Stratifies Risk of Heart Failure in Patients With Acute Leukemia
May 18th 2020Baseline clinical characteristics coupled with measurable cardiac parameters can be used to predict the risk of heart failure among adults with acute leukemia who receive anthracycline-based therapy, according to recent study findings.
Read More
Scoring System Stratifies Risk of Heart Failure in Patients With Acute Leukemia
May 18th 2020Baseline clinical characteristics coupled with measurable cardiac parameters can be used to predict the risk of heart failure among adults with acute leukemia who receive anthracycline-based therapy, according to recent study findings.
Read More
cfDNA Assay Shows Predictive Value in Detecting Cancer, Tissue of Origin
April 29th 2020A cell-free DNA test demonstrated the potential to detect cancer and predict tissue of origin in patients with a suspicion of cancer, according to findings from the Circulating Cell-free Genome Atlas study presented at the 2020 AACR Virtual Annual Meeting I.
Read More